Compare BLIN & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLIN | EDSA |
|---|---|---|
| Founded | 2000 | 2015 |
| Country | United States | Canada |
| Employees | 40 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2M | 12.3M |
| IPO Year | 2007 | N/A |
| Metric | BLIN | EDSA |
|---|---|---|
| Price | $0.73 | $1.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $4.62 | ★ $13.00 |
| AVG Volume (30 Days) | 54.6K | ★ 102.4K |
| Earning Date | 02-12-2026 | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $15,383,000.00 | N/A |
| Revenue This Year | $22.67 | N/A |
| Revenue Next Year | $21.08 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 0.16 | N/A |
| 52 Week Low | $0.69 | $0.94 |
| 52 Week High | $2.22 | $4.49 |
| Indicator | BLIN | EDSA |
|---|---|---|
| Relative Strength Index (RSI) | 37.20 | 25.62 |
| Support Level | $0.73 | $1.06 |
| Resistance Level | $0.84 | $1.34 |
| Average True Range (ATR) | 0.05 | 0.13 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 27.16 | 19.96 |
Bridgeline Digital Inc is a AI-powered marketing technology company that offers a suite of products that help companies grow online revenue by driving more traffic to their websites, converting more visitors to purchasers, and increasing average order value. Company software is available through a cloud-based Software as a Service (SaaS) model. It helps to maximize the performance of critical websites, intranets, and online stores. The company generates revenue from digital engagement services, subscription, perpetual licenses, maintenance, and hosting. Geographically, it derives a majority of revenue from the United States.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.